What's Going On With Penny Stock AgeX Therapeutics?
What's Going On With Penny Stock AgeX Therapeutics?
Serina Therapeutics Inc, a privately held, clinical-stage biotechnology company, entered into a License Agreement under which Pfizer Inc (NYSE:PFE) will license, on a non-exclusive basis, Serina's POZ polymer technology.
Serina Therapeutics Inc是一家處於臨床階段的私營生物技術公司，它簽訂了一項許可協議，根據該協議，輝瑞公司（紐約證券交易所代碼：PFE）將在非排他性的基礎上許可Serina的POZ聚合物技術。
Serina is focused on developing its proprietary POZ Platform drug delivery technology, including POZ lipid nanoparticle (LNP) delivery systems for RNA-based therapeutics.
Serina專注於開發其專有的POZ平台藥物遞送技術，包括用於基於RNA的療法的POZ脂質納米顆粒（LNP）遞送系統。
"We are excited about the license to Pfizer for its use of the POZ polymer technology in initial research and development activities," stated Dr. Milton Harris, Executive Board Chair at Serina Therapeutics. "The license agreement represents an important milestone for Serina."
Serina Therapeutics執行董事會主席米爾頓·哈里斯博士說：“我們很高興輝瑞獲准在初始研發活動中使用POZ聚合物技術。”“許可協議對Serina來說是一個重要的里程碑。”
In August, Serina Therapeutics announced a merger agreement with AgeX Therapeutics Inc (NYSE:AGE) in an all-stock transaction.
8月，Serina Therapeutics宣佈與Agex Therapeutics Inc（紐約證券交易所代碼：AGE）簽訂全股交易合併協議。
The combined company will continue under the Serina Therapeutics name and will focus on advancing the pipeline of small molecule drug candidates targeting central nervous system indications, enabled by the company's proprietary POZ Platform delivery technology.
合併後的公司將繼續使用Serina Therapeutics的名義，並將在公司專有的POZ Platform交付技術支持下，專注於推進靶向中樞神經系統適應症的小分子候選藥物的產品線。
According to data from Benzinga Pro, AgeX Therapeutics stock is trading lower on heavy volume, with a session volume of 9.9 million shares traded, compared to the trailing 100-day volume of 17.29k shares.
根據Benzinga Pro的數據，由於交易量大，Agex Therapeutics的股票交易量走低，交易量爲990萬股，而過去100天的交易量爲17.29萬股。
Price Action: AGE shares are down 28.3% at $0.42 on the last check Friday.
價格走勢：週五上一次支票時，AGE股價下跌28.3％，至0.42美元。